Zoetis, Inc. Class A Aktie News

The flow of information is constant and sometimes overwhelming on Wall Street. Trying to interpret an onslaught of earnings reports and monthly economic data releases each quarter can easily allow something of importance to go unnoticed.

Zoetis Inc. is the dominant animal health company, growing market share, revenue, and margins, now trading at a multi-year low valuation. Fundamentals remain strong: rising EPS, aggressive buybacks, and a shareholder yield of 3.2% with robust secular tailwinds supporting long-term growth. Key franchises (Simparica, Apoquel, Librela) are expanding, protected by patents, into the 2030s-2040s, wit...

I am an adherent to the Gardner-Kretzmann Continuum's strategy of owning at least one stock for each year of your age. Because of this notion, I have 37 "core" holdings that I try to add to consistently over time.

For investors focused on the long game, there is little reason to sell -- at least, so long as a company generates solid returns through consistently improving financial results, regularly increases its dividend (if it pays one), and maintains strong growth prospects. Although it's sometimes difficult to find corporations that can do all that over long periods, stocks of this caliber do exist.

Zoetis remains a compelling long-term investment, driven by strong growth in companion animal products and a resilient pet care market. Despite recent underperformance and valuation concerns, Zoetis's leadership, scale, and innovation position it well against new competitors. Financials show steady revenue, profit, and dividend growth, with management raising full-year guidance and focusing on ...

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2025 financial results and respond to questions from financial analysts during the call. Inves...

The Merck rival faces intense competition that could limit multiple expansion, Stifel analysts say.

U.S. equities were higher at midday as President Donald Trump again called on Federal Reserve Chair Jerome Powell to cut interest rates ahead of today's Fed decision. The Dow Jones Industrial Average, S&P 500, and Nasdaq all gained.